Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.

Hiển thị phiên bản (1) khác

Multiple myeloma is a B-cell malignancy characterized by the accumulation of plasma cells in the bone marrow and the development of osteolytic bone disease. The present study demonstrates that myeloma cells express the critical osteoclastogenic factor RANKL (the ligand for receptor activator of NF-k...

Mô tả đầy đủ

Chi tiết về thư mục
Những tác giả chính:	Croucher, P, Shipman, C, Lippitt, J, Perry, M, Asosingh, K, Hijzen, A, Brabbs, A, van Beek, E, Holen, I, Skerry, T, Dunstan, C, Russell, G, Van Camp, B, Vanderkerken, K
Định dạng:	Journal article
Ngôn ngữ:	English
Được phát hành:	2001

Những quyển sách tương tự

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma
Bằng: Croucher, P, et al.
Được phát hành: (2001)

Osteoprotegerin (OPG) inhibits the development of osteolytic bone disease in the 5T2MM model of multiple myeloma.
Bằng: Croucher, P, et al.
Được phát hành: (2000)

Zoledronic acid inhibits the development of osteolytic bone disease and increases disease free survival in a murine model of multiple myeloma.
Bằng: Croucher, P, et al.
Được phát hành: (2001)

Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
Bằng: Croucher, P, et al.
Được phát hành: (2003)

Zoledronic acid prevents the development of osteolytic bone disease and increases survival in a murine model of multiple myeloma
Bằng: Croucher, P, et al.
Được phát hành: (2002)

Osteoprotegerin and the development of myeloma bone disease
Bằng: Croucher, P, et al.
Được phát hành: (2004)

Myeloma cells isolated from patients with multiple myeloma express osteoprotegerin ligand.
Bằng: Shipman, C, et al.
Được phát hành: (2000)

Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma.
Bằng: Vanderkerken, K, et al.
Được phát hành: (2003)

Myeloma cells can down-regulate release of osteoprotegerin (OPG) from human bone cells - A contributing factor in myeloma bone loss?
Bằng: Shipman, C, et al.
Được phát hành: (2002)

The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma.
Bằng: Shipman, C, et al.
Được phát hành: (2000)

Bone marrow endothelial cells produce osteoprotegerin: Evidence for a role in the development of myeloma bone disease
Bằng: De Leenheer, E, et al.
Được phát hành: (2004)

Zoledronic acid prevents the development of myeloma bone disease and increases survival
Bằng: Shipman, C, et al.
Được phát hành: (2002)

Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.
Bằng: Croucher, P, et al.
Được phát hành: (2003)

Role of osteoprotegerin (OPG) in cancer.
Bằng: Holen, I, et al.
Được phát hành: (2006)

APOMINE (TM), a novel inhibitor of the meyalonate/isoprenoid pathway, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of the myeloma disease in vivo.
Bằng: Croucher, P, et al.
Được phát hành: (2002)

Bisphosphonates--mechanisms of action in multiple myeloma.
Bằng: Shipman, C, et al.
Được phát hành: (2000)

Bisphosphonates and in vivo models of multiple myeloma - Reply
Bằng: Shipman, C, et al.
Được phát hành: (2001)

Tumour cells isolated from patients with multiple myeloma express the critical osteoclastogenic factor, RANKL.
Bằng: Shipman, C, et al.
Được phát hành: (2000)

The role of osteoprotegerin in breast and prostate cancer
Bằng: Holen, I, et al.
Được phát hành: (2002)

Bone marrow endothelial cells express the osteoclastogenic factor RANKL and its decoy receptor OPG: Evidence for a role in the development of myeloma bone disease.
Bằng: De Leenheer, E, et al.
Được phát hành: (2002)

Osteoprotegerin (OPG) is a soluble decoy receptor for TRAIL/Apo2L and can inhibit TRAIL/Apo2L-induced apoptosis of human myeloma cells in vitro.
Bằng: Shipman, C, et al.
Được phát hành: (2002)

Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
Bằng: Shipman, C, et al.
Được phát hành: (2003)

Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells.
Bằng: Holen, I, et al.
Được phát hành: (2002)

Serum osteoprotegerin (OPG) levels and disease progression in prostate cancer patients
Bằng: Eaton, C, et al.
Được phát hành: (2004)

RANKL/RANK/osteoprotegerin system as novel therapeutic target in the treatment of primary bone tumors and osteolytic metastases
Bằng: Anđelković Zlatibor, et al.
Được phát hành: (2004-01-01)

Osteocyte CIITA aggravates osteolytic bone lesions in myeloma
Bằng: Huan Liu, et al.
Được phát hành: (2022-06-01)

Myeloma cells can promote osteoclastic activity rather than osteoclast recruitment in vitro; Evidence from the 5T2MM murine model of myeloma
Bằng: Mueller, G, et al.
Được phát hành: (2004)

5T2MM murine myeloma cells and CD138+ve human myeloma cells promote osteoclastic activity rather than osteoclast formation in vitro
Bằng: Mueller, G, et al.
Được phát hành: (2004)

Apomine, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo.
Bằng: Edwards, C, et al.
Được phát hành: (2007)

Osteoprotegerin is an anti-apoptotic factor produced by prostate cancer cells that is potentially involved in tumour survival and progression.
Bằng: Holen, I, et al.
Được phát hành: (2002)

Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer.
Bằng: Eaton, C, et al.
Được phát hành: (2004)

Osteolytic lesions: Multiple myeloma or prostate cancer?
Bằng: Akshitha Devaraj, MBBS, et al.
Được phát hành: (2023-04-01)

Preventing osteolytic lesions and osteomyelitis in multiple myeloma
Bằng: Aiken Dao, et al.
Được phát hành: (2022-12-01)

Elucidation of molecular basis of osteolytic bone lesions in advanced multiple myeloma
Bằng: Dongyeop Shin, et al.
Được phát hành: (2024-01-01)

Cells of the bone marrow microenvironment protect myeloma cells from apoptosis induced by TRAIL but not by agonists of TRAIL death receptors.
Bằng: Locklin, R, et al.
Được phát hành: (2005)

The antibody MAB8051 directed against osteoprotegerin detects carbonic anhydrase II: implications for association studies with human cancers.
Bằng: Waterman, E, et al.
Được phát hành: (2007)

CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
Bằng: Dongzheng Gai, et al.
Được phát hành: (2022-09-01)

Multiple myeloma presenting as a massive osteolytic lesion at the clivus
Bằng: Domingos Sousa, et al.
Được phát hành: (2020-11-01)

Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma
Bằng: Dirk Hose, et al.
Được phát hành: (2024-12-01)

A loss of host-derived MMP-7 promotes myeloma growth and osteolytic bone disease in vivo
Bằng: Lwin, S, et al.
Được phát hành: (2017)